Ads
related to: meningococcal meningitis immunization (menomune) chart- Meningitis B
Learn More About The Signs &
Symptoms Of Meningitis B.
- FAQs
Discover FAQs About Meningitis B &
Be Prepared With More Facts.
- Vaccine Locator Tool
Locate A Vaccine Provider Near You
With The Vaccine Locator Tool.
- What You Can Do
Find Out What You Can Do To Help
Protect Against Meningitis B.
- Meningitis B
Search results
Results From The WOW.Com Content Network
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. [9] Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. [ 9 ] [ 10 ] The vaccines are between 85 and 100% effective for at least two years. [ 9 ]
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines.
Meningococcal_meningitis_A,C,Y,W-135_Vaccine.png (226 × 536 pixels, file size: 191 KB, MIME type: image/png) This is a file from the Wikimedia Commons . Information from its description page there is shown below.
African meningitis belt countries/regions: vaccinations prior to entry are not required, but highly recommended. International Travel and Health. Chapter 6 - Vaccine-preventable diseases and vaccines (2019 update). World Health Organization. United Nations (2020). Retrieved on 2 December 2020. File:Meningococcal Meningitis Range.svg
The first-of-its-kind shot addresses the five most common causes of meningococcal disease, Pfizer says. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways ...
The first vaccine to prevent meningococcal serogroup B (meningitis B) disease was approved by the European Commission on 22 January 2013. [12] Vaccines offer significant protection from three to five years (plain polysaccharide vaccine Menomune, Mencevax and NmVac-4) to more than eight years (conjugate vaccine Menactra). [13] [14]
A meningococcal polysaccharide vaccine (MPSV4) has been available since the 1970s and is the only meningococcal vaccine licensed for people older than 55. MPSV4 may be used in people 2–55 years old if the MCV4 vaccines are not available or contraindicated. Two meningococcal conjugate vaccines (MCV4) are licensed for use in the U.S. The first ...
The warning from Meningitis Now comes after UK Health Security Agency (UKHSA) figures published last month showed a rise in invasive meningococcal disease (IMD) cases in England.
Ad
related to: meningococcal meningitis immunization (menomune) chart